FDA's Selective Response to the IoM Drug Safety Report

At a press conference held to announce the Food & Drug Administration’s response to the Institute of Medicine’s report on drug safety, the agency’s top brass stressed that FDA is following the committee’s recommendations in its ongoing plan to improve the post-marketing drug safety system.

At first glance, it certainly looks that way: in response to the 25 recommendations from the IoM committee’s September 2006 report, FDA highlighted 18 "recently initiated" policy changes, 14 "new" initiatives, and eight actions announced